PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
- PMID: 37302543
- DOI: 10.1016/j.drudis.2023.103666
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized treatment in oncology. Antibodies against PD-1/PD-L1 and ICI-based combinations are under clinical investigations in multiple cancers, including ovarian cancer. However, the success of ICIs has not materialized in ovarian cancer, which remains one of the few malignancies where ICIs exhibit modest efficacy as either monotherapy or combination therapy. In this review, we summarize completed and ongoing clinical trials of PD-1/PD-L1 blockade in ovarian cancer, categorize the underlying mechanisms of resistance emergence, and introduce candidate approaches to rewire the tumor microenvironment (TME) to potentiate anti-PD-1/PD-L1 antibodies.
Keywords: PD-1/PD-L1 blockade; drug resistance; immune checkpoint inhibitors; ovarian cancer.
Copyright © 2023. Published by Elsevier Ltd.
Similar articles
-
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.Front Med. 2023 Oct;17(5):805-822. doi: 10.1007/s11684-023-1025-7. Epub 2023 Oct 28. Front Med. 2023. PMID: 37897562 Review.
-
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.Int Immunopharmacol. 2023 Feb;115:109638. doi: 10.1016/j.intimp.2022.109638. Epub 2022 Dec 30. Int Immunopharmacol. 2023. PMID: 36587500 Review.
-
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. Oncologist. 2019. PMID: 30819829 Free PMC article. Review.
-
Inhibition of nucleophosmin/B23 sensitizes ovarian cancer cells to immune check-point blockade via PD-L1 in ovarian cancer.J Formos Med Assoc. 2024 Oct;123(10):1045-1056. doi: 10.1016/j.jfma.2024.05.020. Epub 2024 May 31. J Formos Med Assoc. 2024. PMID: 38821736
-
Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".Br J Cancer. 2023 Feb;128(3):461-467. doi: 10.1038/s41416-022-01960-x. Epub 2022 Sep 6. Br J Cancer. 2023. PMID: 36068276 Free PMC article. Review.
Cited by
-
A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy.Mater Today Bio. 2023 Dec 7;24:100904. doi: 10.1016/j.mtbio.2023.100904. eCollection 2024 Feb. Mater Today Bio. 2023. PMID: 38130428 Free PMC article.
-
A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer.Sci Rep. 2024 Jul 31;14(1):17704. doi: 10.1038/s41598-024-66010-3. Sci Rep. 2024. PMID: 39085255 Free PMC article.
-
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.Cancers (Basel). 2024 Jul 15;16(14):2545. doi: 10.3390/cancers16142545. Cancers (Basel). 2024. PMID: 39061184 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
